abstract |
The invention provides CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments, such as single-stranded fragments; and chimeric receptors, including such antibodies, such as chimeric antigen receptors (CAR). Such antibodies are human antibodies, including those that compete for binding to a CD19 with a reference antibody, such as a murine antibody. In some embodiments, the antibodies display similar functional properties as the reference antibody, such as similar binding affinity and/or competitive inhibition properties. Also provided are genetically engineered cells that exhibit chimeric receptors, and the use of such binding molecules and cells for the administration of cellular therapies. |